Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

COGTCogent Biosciences, Inc.Running, no new patients

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Intrahepatic Cholangiocarcinoma (Icc) · Cholangiocarcinoma · Other Solid Tumors, Adult · FGFR2 Gene Fusion/Rearrangement · FGFR2 Gene Amplification · FGFR2 Gene Short Variants · FGFR3 Gene Fusion/Rearrangement · FGFR3 Gene Amplification · FGFR3 Gene Short Variants · FGFR2 Genetic Alterations · FGFR3 Genetic Alterations · Advanced Solid Tumors

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 1/2
Patients
110 (planned)
Started
Jan 22, 2025
Main results expected
Mar 2027
Fully finished
Jun 2027
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - AEs

    Measured over: Approximately 12 months

  • Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - Laboratory results

    Measured over: Approximately 12 months

  • Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - ECG results

    Measured over: Approximately 12 months

  • Phase 2: Evaluate antitumor activity of CGT4859 - Objective Response Rate (ORR)

    Measured over: Approximately 8 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT06777316 · record last updated 2026-04-17 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06777316) ↗